Abbott Laboratories Corporation

Suzette Pereira

Pradip Mukerji

Yung-Sheng Huang

Jennifer M Thurmond

Tapas Das

Amanda Eun-Yeong Leonard

Padmavathy Krishnan

Neile Edens

Tapas Kumar Das

Amanda E Leonard

Paul W Johns

Normanella Dewille

Sean Garvey

Raj Chandran

Gaurav Patel

Gerard Davis

Guarav Patel

Menghua Luo

Susan Gawel

Disclosed herein are shelf-stable, clear liquid nutritional compositions having a pH ranging from 2.5 to 4.6 and comprising water; at least one source of EGCg in an amount sufficient to provide 200-1700 mg/L of EGCg; and at least one source of protein in an amount sufficient to provide 25-45 g/L of total protein. The shelf-stable, clear liquid nutritional compositions lose no more than 20% by weight solids of the EGCg content present in the initial formulation of the compositions to epimerization, degradation, or both epimerization and degradation during heat sterilization. In certain embodiments, the loss of EGCg is exhibited by the amount of epimerization product GCg present in the shelf-stable, clear liquid nutritional composition following heat sterilization. Methods for preparing the shelf-stable, clear liquid nutritional compositions are also disclosed herein.

Shelf-stable, clear liquid nutritional compositions comprising epigallocatechin gallate (EGCg) and methods for preparing the same

Methods of decreasing muscle function decline and improving muscle function in a subject are provided. The methods utilize an effective amount of epigallocatechin-3-gallate (EGCg) to increase the level of muscle vascular endothelial growth factor A (VEGF), to decrease myostatin levels, or both, and thereby decrease muscle function decline or improve muscle function. The EGCg may be provided as part of a nutritional composition.

Methods of maintaining and improving muscle function

Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.

Treatment of insulin resistance associated with prolonged physical inactivity

Shelf-stable, clear liquid nutritional compositions comprising epigallocatechin gallate (EGCG) and methods for preparing the same

Disclosed herein are methods for enhancing the efficacy of epigallocatechin gallate ('EGCg') in mitigating skeletal muscle loss in a subject. Providing EGCg to a subject in a nutritional composition reduces muscle protein degradation, thereby mitigating skeletal muscle loss in the subject. The combination of EGCg with zinc in a nutritional composition enhances the mitigating effect that EGCg has on muscle loss. Specifically, when used in combination, a nutritional composition containing both EGCg and zinc requires less EGCg to obtain the same mitigating effect that occurs in the same nutritional composition containing EGCg but no zinc.

Methods for enhancing the effect of EGCg on mitigating skeletal muscle loss

Disclosed are antibodies that specifically recognize &#x394;5-desaturase, methods of producing the antibodies, nucleotides and polypeptides for producing the antibodies, and methods of using the antibodies. The &#x394;5-desaturase-specific antibodies provide improved methods of detecting &#x394;5-desaturase in a sample.

Antibodies against delta-5 desaturase and uses thereof

The subject invention relates to the identification of a gene involved in the elongation of polyunsaturated fatty acids containing unsaturation at the carbon 9 position (i.e., '&#x394;9-elongase') and to uses thereof. In particular, &#x394;9-elongase may be utilized, for example, in the conversion of linoleic acid (LA, 18:2n-6) to eicosadienoic acid (EDA, 20:2n-6). The production of dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) from eicosadienoic acid (EDA, 20:2n-6), and arachidonic acid (AA, 20:4n-6) from dihomo-&#x3b3;-linolenic acid (DGLA, 20:3n-6) is then catalyzed by &#x394;8-desaturase and &#x394;5-desaturase, respectively. AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Elongase gene and uses thereof

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 6 (i.e., '&#x394;6-desaturase'). In particular, &#x394;6-desaturase may be utilized, for example, in the conversion of linoleic acid to &#x3b3;-linolenic acid and in the conversion of &#x3b1;-linolenic acid stearidonic acid. The polyunsaturated fatty acids produced by use of the enzyme may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;6-desaturase genes and uses thereof

The present invention is related to isolated polynucleotides encoding a delta-8 desaturase, delta-8 desaturases encoded by the isolated polynucleotides, expression vectors containing the isolated polynucleotides, host cells containing the expression vectors and methods for producing delta-8 desaturases and polyunsaturated fatty acids.

Delta-8 desaturase genes, enzymes encoded thereby and uses thereof

The present disclosure relates to isolated polynucleotides encoding a delta 9-elongase, delta 9-elongases encoded by the isolated polynucleotides, expression vectors comprising the isolated polynucleotides, host cells comprising the expression vectors, and methods for producing delta 9-elongase and polyunsaturated fatty acids.

&#x394;9-elongase for production of polyunsaturated fatty acid-enriched oils

The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., '&#x394;5-desaturase') and at carbon 6 (i.e., '&#x394;6-desaturase') and to uses thereof. In particular, &#x394;5-desaturase may be utilized, for example, in the conversion of dihomo-&#x3b3;-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to &#x3b3;-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

&#x394;-6 desaturase and uses thereof

Delta-5 desaturase and uses thereof

Disclosed are isolated polynucleotides encoding an omega-3 desaturase and a delta-12 desaturase, the enzymes encoded by the isolated polynucleotides, vectors containing the isolated polynucleotides, transgenic hosts that contain the isolated polynucleotides that express the enzymes encoded thereby, methods for producing the desaturase enzymes, and method of using the enzymes to make polyunsaturated fatty acids. The isolated polynucleotides are derived from a fungus,(ATCC 56851). In particular, omega-3-desaturase may be utilized, for example, in the conversion of arachidonic acid (AA) to eicosapentaenoic acid (EPA). Delta-12 desaturase may be used, for example, in the conversion of oleic acid (OA) to linoleic (LA). EPA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Desaturase genes, enzymes encoded thereby, and uses thereof

The subject invention relates to the identification of several genes involved in the elongation of polyunsaturated fatty acids (i.e., 'elongases') and to uses thereof. At least two of these genes are also involved in the elongation of monounsaturated fatty acids. In particular, elongase is utilized in the conversion of gamma linolenic acid (GLA) to dihomogamma linolenic acid (DGLA) and in the conversion of AA to adrenic acid (ADA), or eicosapentaenoic acid (EPA) to &#x3c9;3-docosapentaenoic acid (DPA). DGLA may be utilized in the production of polyunsaturated fatty acids, such as arachidonic acid (AA), docosahexaenoic acid (DHA), EPA, adrenic acid, &#x3c9;6-docosapentaenoic acid or &#x3c9;3-docosapentaenoic acid which may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics.

Growing community of inventors

Westerville, OH, United States of America

Suzette Pereira